Pharmafile Logo
Pharmafocus logo
Advanced Search

Regeneron

Showing 15 posts of 97 posts found.

regeneron

Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy

March 20, 2018
Manufacturing and Production, Research and Development Eylea, Regeneron, diabetes, pharma

Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …

News
shutterstock_36423250

Sanofi and Regeneron reveal strong data and a price drop for Praluent

March 12, 2018
Research and Development, Sales and Marketing Regeneron, Sanofi, pharma, praluent

Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within …

News
regeneron

Appeal could throw spanner in the works for Regeneron’s Irish expansion

March 9, 2018
Manufacturing and Production, Medical Communications Ireland, Regeneron, pharma

Regeneron is facing a single man-sized obstacle in plans to expand operations at its campus in Limerick, Ireland with a …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

News
regeneron

Reports increasing of worrying side-effects with Regeneron’s Eylea

February 22, 2018
Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma

Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …

News
eylea-product-box-md

Regeneron forced to drop Eylea combo, advantage Novartis

November 27, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical

Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …

News
regeneron

Regeneron injects $100 million and 300 new roles into Irish production facility

October 26, 2017
Manufacturing and Production Regeneron, Sanofi, manufacturing, pharma

Sanofi subsidiary Regeneron has announced its intention to expand its production plant in Limerick, Ireland – the largest scale bulk …

News
peanuts

Peanut allergies? There’s a clinical trial looking to fix that

October 17, 2017
Manufacturing and Production, Research and Development Aimmune, Regeneron, Sanofi, biotech, drugs, peanuts, pharma, pharmaceutical

Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …

News
sanofi_regeneron

Sanofi and Regeneron’s projected blockbuster gains EU approval

September 28, 2017
Sales and Marketing Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron have big hopes for their treatment Dupixent, and it has taken an important step towards reaching the …

News
sanofi_regeneron

Sanofi/Regeneron new asthma data bolstered by potential indications

September 13, 2017
Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …

News
regeneron

Regeneron abandons respiratory syncytial virus therapy after late-stage failure

August 15, 2017
Manufacturing and Production, Research and Development RSV, Regeneron, pharma, pharmaceuticals, respiratory syncytial virus

Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the …

News
sanofi_regeneron

New potential blockbuster RA treatment enters European market

June 27, 2017
Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi

The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …

News

Novartis receives positive news in eye drug P3 studies

June 20, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron

Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it …

News

Sanofi and Regeneron posts positive Praluent cholesterol data

June 12, 2017
Research and Development, Sales and Marketing Regeneron, Sanofi, praluent

Sanofi and Regeneron were able to update its PCSK9 therapy Praluent with the positive data showing it could reduce levels …

News

FDA approves first-ever atopic dermatitis biologic treatment

March 31, 2017
Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic

Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023